Phase 2 Leukaemia Trial, Recruiting NCT05194397 Sponsor: Children's Hospital of Philadelphia Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT05194397
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 10 and 30 years old
  • You are able to speak and understand English
  • You have been diagnosed with leukemia, aplastic anemia, bone marrow failure syndrome, or myelodysplastic syndrome, and received a bone marrow/stem cell transplant from a donor to treat it
  • It has been between 6 and 48 months since your donor transplant
  • If you are female, you must have a negative pregnancy test and agree to use an approved form of birth control (such as abstinence, condoms, or the pill) for the whole study
  • You or your parent/guardian are willing and able to give permission to take part, and if you are a child, you are willing to agree to join
  • You weigh at least 24 kg (about 53 pounds)

Who may not be able to join:

  • You have a known allergy or sensitivity to a supplement called nicotinamide riboside (NR) (confirm with trial site)
  • You are currently taking medications, including statins (cholesterol drugs), that could increase the risk of side effects from NR
  • You currently have active cancer, have taken an experimental drug in the last 4 weeks, or are taking high-dose steroid medicines
  • You already meet the public health guidelines for regular exercise
  • You have taken high-dose NAD+ supplement products in the last 4 weeks (confirm with trial site)
  • Your red blood cell levels (hemoglobin) are too low (below 10 g/dL)
  • Your platelet count is too low (below 50,000)
  • You have diabetes that requires insulin or certain diabetes medicines (confirm with trial site)
  • Your blood sugar control is too poor, based on a blood test called HbA1c or a fasting blood sugar test (if you have diabetes, both tests must meet the required levels)
  • You have kidney disease affecting how well your kidneys filter your blood
  • You have liver disease, shown by certain liver enzyme levels being more than 3 times the normal range
  • You have a physical condition that prevents you from doing exercise testing or training
  • You have unstable chest pain or had a heart attack within 5 days of starting study activities
  • You have frequent fainting episodes
  • You have severe narrowing of the main heart valve (aortic stenosis) causing symptoms
  • You have an uncontrolled irregular heartbeat that causes symptoms
  • You had a blood clot in the lungs within the last 3 months
  • You have a blood clot in the veins of your legs
  • You have moderate or severe persistent asthma that causes symptoms, based on a breathing test done before your transplant
  • Your blood oxygen level drops to 85% or below when resting and breathing normal air
  • You are female and are pregnant or planning to become pregnant
  • You have a non-heart or lung condition that could affect your ability to exercise or be made worse by exercise (for example, active infection, kidney failure, thyroid problems, or moderate-to-severe graft-versus-host disease causing physical problems)
  • The trial team believes you or your parent/guardian may have difficulty following the study schedule or procedures
  • You have a reason you cannot safely have an MRI scan (note: if you cannot complete the MRI, you may still be able to take part in other parts of the study — confirm with trial site)
  • Your current weight means it would not be safe for you to complete the study activities

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sogol Mostoufi-Moab, MD, MSCE, Children's Hospital of Philadelphia

Phone: 445-942-7801

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Children's Hospital of Philadelphia
Registry
ClinicalTrials.gov
Start date
23 February 2023
Est. completion
30 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Within participant changes in muscle strength (Isometric knee extension, Z-score)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov